SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms
Biomolecules · 15.06.2026 · 16 (6) · 873
DOI: 10.3390/biom16060873 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 15.06.2026. Verfasst von Khrystyna Ryabenko und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna, 40138 Bologna, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Cardiomyopathy, Hypertrophic, Sodium-Glucose Transporter 2. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disorder and a major cause of heart failure (HF) and sudden cardiac death. Although sarcomeric gene mutations initiate the disease, increasing evidence identifies oxidative stress, mitochondrial dysfunction, and maladaptive nutrient signaling as key drivers of disease progression. Enhanced reactive oxygen species (ROS) production in HCM promotes energetic impairment, calcium mishandling, fibrosis, and the activation of pro-hypertrophic pathways, while disrupting protein quality control and endothelial function. Despite recent therapeutic advances, effective disease-modifying strategies targeting these molecular mechanisms remain limited. Sodium–glucose cotransporter 2 inhibitors (SGLT2i), originally developed for type 2 diabetes, have demonstrated robust cardioprotective effects in HF independent of glycemic control. Beyond their renal actions, SGLT2i modulate myocardial metabolism, reduce oxidative stress, improve mitochondrial function, restore sodium and calcium homeostasis, and attenuate inflammation and maladaptive mTOR activation. Emerging preclinical and translational data suggest that these pleiotropic mechanisms may counteract key pathophysiological processes underlying HCM. This review summarizes the molecular interplay between oxidative stress and hypertrophic remodeling in HCM and explores the rationale for SGLT2 inhibition as a potential disease-modifying therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna, 40138 Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
- UR 3074-Translational CardioVascular Medicine, Faculty of Pharmacy, University of Strasbourg, 67000 Strasbourg, France.
- Division of Cardiovascular Medicine, Nouvel Hospital Civil, Strasbourg University Hospital, 67000 Strasbourg, France.
- UMR 7357-ICube, CNRS-University of Strabourg, 67084 Strasbourg, France.
ORCID-Profile: Khrystyna Ryabenko, Valérie Schini-Kerth, Patrick Ohlmann
Zitieren
APA
Ryabenko, K., Schini-Kerth, V., Ohlmann, P., & Galli, E. (2026). SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms. Biomolecules, 16(6), 873. https://doi.org/10.3390/biom16060873
Vancouver
Ryabenko K, Schini-Kerth V, Ohlmann P, Galli E. SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms. Biomolecules. 2026;16(6):873. doi:10.3390/biom16060873
BibTeX
@article{Ryabenko2026,
author = {Ryabenko, Khrystyna and Schini-Kerth, Valérie and Ohlmann, Patrick and Galli, Elena},
title = {SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {6},
pages = {873},
doi = {10.3390/biom16060873}
}
EUVIMED